A Joint Scientific Consultation (JSC) enables health technology developers (HTDs) to seek scientific advice on the evidence likely to be required for a subsequent Joint Clinical Assessment (JCA) while clinical studies are still being planned. It supports early decisions on patient populations, comparators, outcomes and statistical analyses without prejudging the subsequent assessment.
JSC is a separate procedure under Regulation (EU) 2021/2282. The HTD submits a request during a published request period, sets out its questions in a briefing package and discusses outstanding issues with the experts involved. The process results in a JSC outcome document containing scientific recommendations that are not legally binding.
Joint Scientific Consultation as early scientific advice under EU HTA
JSC addresses evidence generation plans for a health technology likely to undergo a subsequent JCA. It is intended to take place while the clinical development programme can still be adapted.
For medicinal products, discussions primarily concern the design of planned clinical studies, the patient population, the intervention, relevant comparators and clinical outcomes. Questions may also cover statistical analyses, subgroups, patient-reported outcomes and post-launch evidence generation.
JSC differs from JCA: JSC provides scientific recommendations on planned evidence generation, whereas JCA assesses the available clinical evidence against the final assessment scope. The subsequent assessment process is explained in the guide Joint Clinical Assessment (JCA): Process, timelines and requirements under EU HTA.
Eligibility for Joint Scientific Consultation
A health technology may be eligible for JSC if it is likely to undergo JCA and the relevant clinical studies or investigations are still at the planning stage. Timing matters because advice can influence a study design only while decisions remain open.
For medicinal products, an HTD may request JSC for a new product or for a new indication of an existing medicinal product, provided the eligibility requirements are met. The request describes the product, intended indication, regulatory status, previous scientific advice and planned clinical development programme.
The JSC request template includes areas such as study design, statistical methods and post-launch evidence generation (PLEG). Other substantiated questions may be considered depending on the procedure. In a parallel HTACG/EMA consultation, regulatory questions also fall within the EMA's remit.
Requesting and selecting a Joint Scientific Consultation
An HTD submits its JSC request through the EU HTA IT platform during a designated request period. Under Article 2 of Commission Implementing Regulation (EU) 2024/3169, the HTA Coordination Group sets the request periods and planned consultation numbers for the following year by 30 November. At least three request periods per year must be provided for medicinal products.
JSC request and required information
The HTD describes the health technology, intended indication and clinical development programme, identifies the areas on which advice is sought and explains why the proposed evidence generation requires scientific consultation.
The request may need to provide initial information on population, intervention, comparators, outcomes and planned study design. It is distinct from the more detailed briefing package submitted after the request is accepted.
Selection where JSC capacity is limited
Where eligible requests exceed the number of consultations planned, six selection criteria under Article 17(3) of Regulation (EU) 2021/2282 apply. These are not six cumulative eligibility conditions. Requests involving technologies with similar intended indications must be treated equally.
Unmet medical needs.
First in class.
Potential impact on patients, public health or healthcare systems.
Significant cross-border dimension.
Major Union-wide added value.
Union clinical research priorities.
Within 15 working days after the end of the request period, the Coordination Group informs the HTD whether it will undertake the JSC. A refusal must be explained with reference to the selection criteria (Article 17(4) of Regulation (EU) 2021/2282).
The Joint Scientific Consultation process in four phases
JSC proceeds from the initial request through scientific preparation and a consultation meeting to the outcome document. An assessor and a co-assessor from different Member States lead the scientific work within the designated JSC structures.
|
Phase |
Main activity |
Output |
|---|---|---|
|
1. Request and selection |
Submission, eligibility and selection |
Decision to undertake JSC |
|
2. Briefing package |
Submission and scientific review |
Basis for consultation |
|
3. List of issues and meeting |
Written clarification and discussion |
Scientific positions and advice topics |
|
4. Outcome document |
Drafting, review and finalisation |
Written scientific recommendations |
Phase 1: JSC request and appointment of participants
Once the request has been selected, an assessor and co-assessor from different Member States are appointed. Eligible individual experts, patients and clinical experts may contribute to the scientific consultation, subject to the relevant conflict-of-interest checks. The request procedure and the 15-working-day selection period are explained in the preceding section.
Phase 2: Briefing package and scientific preparation
After acceptance, the HTD prepares the briefing package using the prescribed template and submits it via the HTA IT platform by the deadline specified in the individual JSC timetable (Article 7(2) of Implementing Regulation (EU) 2024/3169). The package sets out the development programme, specific questions and the HTD's scientifically justified positions. An amended package may be requested where information or clarification is missing.
Phase 3: List of issues and JSC meeting
The list of issues is developed after review of the briefing package and communicated to the HTD. It may identify matters for discussion at the meeting and questions requiring written answers only. Written responses and any necessary meeting materials must be submitted no later than 10 days before the meeting (Article 9(1) of Implementing Regulation (EU) 2024/3169).
Phase 4: Preparation of the JSC outcome document
After the meeting, the assessor and co-assessor prepare the draft outcome document. Following internal comments, finalisation and approval under the applicable procedure, the document is sent to the HTD. It records scientific recommendations but does not bind the subsequent JCA.
PICO considerations and study design in Joint Scientific Consultation
JSC allows the HTD to discuss whether the proposed study design anticipates likely European HTA evidence requirements. Advice may address population, intervention, comparators and outcomes, as well as statistical methods and additional evidence generation.
Patient populations and comparators in study planning
The HTD may ask whether the proposed inclusion and exclusion criteria capture clinically relevant groups and whether planned comparators are appropriate for anticipated European assessment questions. Differences in national standards of care may suggest additional comparator scenarios.
JSC does not establish the final assessment scope for a subsequent JCA. The separate guide JCA scoping and PICO: Assessment scope, comparators and evidence planning under EU HTA explains how Member States' PICO requirements are collected and consolidated.
The role that the choice of evidence-based comparators also plays for regulatory incentives is discussed in the insight EU Pharmaceutical Reform 2026 and orphan drug market exclusivity.
Outcomes and statistical planning
Scientific advice may cover clinical outcomes, patient-reported measures, subgroup definitions and key features of the statistical analysis plan. HTDs should present concrete choices and alternatives, rather than asking for a general endorsement of the development programme.
JSC addresses planned evidence generation rather than retrospective appraisal of completed analyses. The methodology of later clinical assessment is covered in JCA evidence assessment: Methodological requirements for RCTs, indirect comparisons and non-randomised evidence.
Briefing package for Joint Scientific Consultation
The JSC briefing package provides the scientific basis for consultation and is submitted via the HTA IT platform by the deadline in the individual timetable. It should describe the technology, development programme and questions clearly enough for assessors and experts to appraise the HTD's proposals.
Disease background and treatment landscape
This section describes the disease, its clinical course, current care and unmet therapeutic needs. It identifies relevant treatment options and their position in the treatment pathway, explaining the clinical questions the development programme aims to answer.
Product and intended indication
The briefing package describes the medicinal product, its proposed use and intended indication. These details must be consistent with the development programme and consultation questions. Ambiguity about the target population or treatment setting can hinder assessment of the study plan.
Clinical development programme
The HTD presents completed and ongoing studies and planned development steps, distinguishing available evidence from questions that future studies are intended to address.
Planned clinical studies
The study plan should provide sufficient detail on populations, treatment arms, comparators, outcomes and key statistical choices. Alternative designs should be accompanied by a scientific rationale.
Evidence gaps and post-launch evidence generation
The briefing package may identify anticipated evidence gaps relevant to a future JCA. The template also provides for discussion of post-launch evidence generation (PLEG), particularly in connection with pivotal study design. Topics may include outstanding research questions, data sources, populations, comparators, outcomes and timelines.
Questions and HTD positions in the JSC briefing package
Focused questions and the corresponding HTD positions form the core of the scientific argument in a JSC briefing package. Each question should identify a concrete development decision and specify the proposed approach on which advice is requested.
The briefing document template recommends no more than ten focused questions, preferably with only one or two subquestions each. A separate HTD position should accompany each question.
Scientific rationale for an HTD position
The HTD position explains and justifies the proposed approach using the available scientific evidence. Depending on the issue, it may discuss alternatives, benefits and limitations, potential consequences and mitigation measures.
The template generally recommends one to three pages per position. Complex statistical proposals should be supported by relevant literature and transparent assumptions.
Questions seeking future reimbursement decisions or binding recognition of added clinical benefit are outside the intended remit of European JSC.
Preparing for the list of issues and the JSC meeting
The list of issues brings together the scientific matters to be clarified before and during the consultation meeting. The HTD should prepare the supporting evidence, assumptions and possible alternatives for each position.
Written responses to the list of issues
The list may distinguish meeting topics from questions to be answered exclusively in writing. The HTD submits written responses and necessary materials or presentations no later than 10 days before the meeting (Article 9(1) of Implementing Regulation (EU) 2024/3169). Responses should address each question directly and provide a traceable scientific rationale.
Scientific preparation for the JSC meeting
Participants include the HTD, assessor and co-assessor, selected individual experts, other JSC Subgroup representatives and the HTA secretariat. A virtual meeting is expressly required for parallel JSC/EMA scientific advice; Article 12 of Implementing Regulation (EU) 2024/3169 does not impose that format on every stand-alone JSC. Where the consultation is parallel, EMA participants also attend. Coordination among Clinical Development, Biostatistics, Regulatory Affairs, HEOR and Market Access helps ensure consistent answers.
Parallel HTACG/EMA JSC: Coordinated scientific advice
A parallel HTACG/EMA JSC aligns European HTA consultation with EMA scientific advice while maintaining separate institutional responsibilities.
The HTD requests both JSC and EMA scientific advice. Timetables are synchronised and the agreed parallel briefing-package template is submitted simultaneously to the HTA secretariat and EMA (Articles 7 and 8 of Implementing Regulation (EU) 2024/3169). The joint meeting is virtual and co-chaired by the JSC assessor or co-assessor and an EMA scientific advice coordinator (Article 12(3)).
|
HTACG JSC |
Parallel HTACG/EMA JSC |
|---|---|
|
Advice on HTA-relevant evidence generation |
Coordinated advice on HTA and regulatory questions |
|
HTACG structures participate |
HTACG and EMA participate |
|
JSC outcome document |
JSC outcome document and EMA scientific advice |
Parallel consultation does not produce a joint marketing-authorisation or HTA decision.
Changes to the clinical development plan before the JSC meeting
Updates to an amended development plan submitted after the revised briefing package are taken into account in the outcome document if received no later than 10 days before the meeting. This rule (Article 13(1) of Implementing Regulation (EU) 2024/3169) is distinct from the deadline for written responses to the list of issues.
For parallel EMA scientific advice, relevant updates must be submitted to both the HTA secretariat and EMA at the same time.
JSC outcome document: Results and legal status
The JSC outcome document records scientific recommendations and is not legally binding. It reflects the evidence and scientific understanding available at the time of consultation and neither determines the later assessment scope nor prejudges a subsequent JCA.
The Coordination Group approves the outcome document. The Commission sends it to the HTD no later than 10 working days after finalisation (Article 19(1)–(2) of Regulation (EU) 2021/2282). Under Article 16(3), it has no legal effect on the HTD, the Coordination Group or Member States.
Confidential, consultation-specific material is not generally published. Anonymised, aggregated and non-confidential information about consultations may be made public.
Relationship between Joint Scientific Consultation and Joint Clinical Assessment
JSC informs the planning of clinical evidence generation; the later JCA evaluates the comparative evidence actually available. The procedures are linked but serve distinct purposes.
A JSC briefing package may identify gaps relevant to a future JCA. Nevertheless, the final PICO requirements may differ from the scenarios discussed during consultation.
Where a medicinal product has undergone JSC, the HTD must explain in its subsequent JCA dossier any deviation from the recommended evidence (Annex I(e) to Regulation (EU) 2021/2282). This explanation belongs in the JCA dossier, not in a retrospective amendment to the JSC outcome document.
The sequence is: JSC → clinical evidence generation → JCA scoping → JCA dossier → joint clinical assessment.
Joint Scientific Consultation and national scientific advice
European JSC does not generally prevent additional scientific advice at national level. National advice can address requirements specific to a national HTA system.
In Germany, this may include consultation with the Federal Joint Committee (G-BA); eligibility and preparation are described in the guide to G-BA consultation. In France, opportunities for scientific advice must be distinguished from subsequent assessment by the Haute Autorité de santé (HAS) and national dossier submission.
An aligned advice strategy can help the HTD reconcile European evidence-generation questions with country-specific requirements and avoid unnecessary duplication or conflicting proposals.
Sources and regulatory framework
Regulation (EU) 2021/2282, particularly Articles 16–21 and Annex I(e).
Commission Implementing Regulation (EU) 2024/3169, particularly Articles 2–4, 7–9, 12 and 13.
European Commission and HTA Coordination Group: JSC request template and associated application materials.
European Commission and HTA Coordination Group: JSC briefing document template and procedural materials.
Regulatory source date: October 2026. Selection criteria and statutory deadlines are based on the two EU regulations above. Individual request-period dates, case-specific timetables and template requirements should be checked against the latest HTA Coordination Group publications.